bovnews1d
The Myriad Genetics Inc Enigma: What’s Causing the Wild Swings in MYGN Stock?
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference
The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...
Zacks.com on MSN6d
MYGN Stock Gains Following the Launch of Know More Sooner
Myriad Genetics, Inc. MYGN recently launched a new educational website, Know More Sooner, which provides comprehensive ...
Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now?
We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a ...
Myriad Genetics: Navigating Through A Setback
Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...
Forbes6d
Myriad Genetics
Myriad Genetics, Inc. is a molecular diagnostic company, which focuses on developing and marketing of novel predictive and personalized medicines and prognostic medicine tests. It operates through ...
Yahoo Finance6d
Myriad Genetics, Inc. (MYGN)
In this article, we are going to take a look at where Myriad Genetics, Inc. (NASDAQ:MYGN) stands against Larry Robbins’ other long-term stock picks. Larry Robbins is an American hedge fund ...
Myriad Genetics Introduces Online Prenatal Genetic Testing Resource
SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...
bovnews12d
Myriad Genetics Inc (MYGN) Posted -14.08% Profit Margin Last Year—Can It Hold Up?
Myriad Genetics Inc (MYGN) stock saw a decline, ending the day at $12.39 which represents a decrease of $-0.13 or -1.04% from the prior close of $12.52. The stock opened at $12.56 and touched a low of ...
manilatimes1mon
NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris® Test as an 'Advanced Tool' Recommended for Prognostic Assessment
SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that its Prolaris prostate cancer prognostic ...
The Bakersfield Californian1d
Myriad Genetics Unveils Groundbreaking Eight Weeks’ Gestation NIPT Study Results at Society for ...
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research at ...
CNN9d
Myriad Genetics, Inc.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...